Suggested remit - To appraise the clinical and cost effectiveness of brentuximab vedotin within its marketing authorisation for untreated advanced Hodgkin lymphoma.
Awaiting trial results
Status Suspended
Process STA 2018
ID number 1258

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
13 August 2019 Suspended. Awaiting trial results
03 July 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brentuximab vedotin for untreated advanced Hodgkin lymphoma. Following an update from the company, the timelines for this appraisal are to be confirmed whilst the company await the final results of a key study being undertaken in this indication. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization. NICE will continue to monitor development and will update interested parties as and when the situation changes.
06 February 2018 - 06 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress. In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance